Cargando…

PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer

Targeted nanotheranostic systems offer significant benefits due to the integration of diagnostic and therapeutic functionality, promoting personalized medicine. In recent years, prostate-specific membrane antigen (PSMA) has emerged as an ideal theranostic target, fueling multiple new drug approvals...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meher, Niranjan, VanBrocklin, Henry F., Wilson, David M., Flavell, Robert R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964110/ https://www.ncbi.nlm.nih.gov/pubmed/37259457 http://dx.doi.org/10.3390/ph16020315

Ejemplares similares

Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers
por: Meher, Niranjan, et al.
Publicado: (2022)

Evaluation of (134)Ce/(134)La as a PET Imaging Theranostic Pair for (225)Ac α-Radiotherapeutics
por: Bobba, Kondapa Naidu, et al.
Publicado: (2023)

Treatment of Prostate Cancer with CD46-targeted (225)Ac Alpha Particle Radioimmunotherapy
por: Bidkar, Anil P., et al.
Publicado: (2023)

Seeing Is Believing: Nuclear Imaging of HIV Persistence
por: Henrich, Timothy J., et al.
Publicado: (2019)

Radiolabeled Small Molecule Protein Kinase Inhibitors for Imaging with PET or SPECT
por: Hicks, Justin W., et al.
Publicado: (2010)

Targeted Magnetic Nanotheranostics of Cancer
por: Belyanina, Irina, et al.
Publicado: (2017)

PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy
por: Rybalov, Maxim, et al.
Publicado: (2014)

Nanotheranostics for Image-Guided Cancer Treatment
por: Dennahy, Isabel S., et al.
Publicado: (2022)

Cancer nanotheranostics
por: Gopinath, P, et al.
Publicado: (2015)

Multimodality imaging in nanomedicine and nanotheranostics
por: Li, Xue, et al.
Publicado: (2016)

Nanotheranostics Targeting the Tumor Microenvironment
por: Roma-Rodrigues, Catarina, et al.
Publicado: (2019)

Image-guided drug delivery of nanotheranostics for targeted lung cancer therapy
por: Yin, Xiaoran, et al.
Publicado: (2022)

Imaging Active Infection in vivo Using D-Amino Acid Derived PET Radiotracers
por: Neumann, Kiel D., et al.
Publicado: (2017)

Nanotheranostics for cancer applications
por: Rai, Prakash, et al.
Publicado: (2018)

MXenes in Cancer Nanotheranostics
por: Iravani, Siavash, et al.
Publicado: (2022)

PSMA PET in Imaging Prostate Cancer
por: Tsechelidis, Ioannis, et al.
Publicado: (2022)

Phosphatidylserine-Targeted Nanotheranostics for Brain Tumor Imaging and Therapeutic Potential
por: Wang, Lulu, et al.
Publicado: (2017)

Nanotheranostics With the Combination of Improved Targeting, Therapeutic Effects, and Molecular Imaging
por: Peng, Shin-Lei, et al.
Publicado: (2020)

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
por: Schottelius, Margret, et al.
Publicado: (2019)

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
por: Stefan A. Koerber, et al.
Publicado: (2020)

Value of Targeted Biopsies and Combined PSMA PET/CT and mp-MRI Imaging in Locally Recurrent Prostate Cancer after Primary Radiotherapy
por: Rasing, Marnix, et al.
Publicado: (2022)

Introduction to nanotheranostics
por: Tamil Selvan, Subramanian, et al.
Publicado: (2016)

Supramolecular Nanotheranostics
por: Chen, Xiaoyuan, et al.
Publicado: (2019)

PSMA-targeted imaging of prostate cancer: evolution of a success story
por: Maurer, Tobias, et al.
Publicado: (2017)

PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
por: Flores, Orielyz, et al.
Publicado: (2017)

PSMA-targeted therapy for non-prostate cancers
por: Wang, Jarey H., et al.
Publicado: (2023)

Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Nanotheranostic Applications for Detection and Targeting Neurodegenerative Diseases
por: Kumar, Ajay, et al.
Publicado: (2020)

Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
por: Derks, Yvonne H. W., et al.
Publicado: (2023)

Imaging the Urokinase Plasminongen Activator Receptor in Preclinical Breast Cancer Models of Acquired Drug Resistance
por: LeBeau, Aaron M., et al.
Publicado: (2014)

Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors
por: Ngen, Ethel J., et al.
Publicado: (2021)

Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT
por: Karagiannis, Vasileios, et al.
Publicado: (2022)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

A Boronate-Caged [(18)F]FLT Probe for Hydrogen Peroxide Detection Using Positron Emission Tomography
por: Carroll, Valerie, et al.
Publicado: (2014)

PSMA PET imaging in the diagnosis and management of prostate cancer
por: Houshmand, Sina, et al.
Publicado: (2023)

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model
por: Lundmark, Fanny, et al.
Publicado: (2020)

The Role of Magnetic Nanoparticles in Cancer Nanotheranostics
por: Ferreira, Maria, et al.
Publicado: (2020)

Engineering nanotheranostic strategies for liver cancer
por: Cao, Lei, et al.
Publicado: (2021)

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ici4sp7rchi3bs1e24ltl97p2l